Vertex Pharmaceuticals Inc / Ma
Held by 14 tracked managers as of Q2 2026 · CUSIP ⓘCUSIP: A 9-character ID for one specific security - one share class of one company, or one bond. Tickers can change and can mean different things in different countries; a CUSIP always identifies exactly the same security, which is why filings use it. Guide 92532F100 · Sector ⓘGICS sectors: The 11-sector system most investors know (Global Industry Classification Standard): Technology, Health Care, Financials and so on. This site assigns each company a GICS-style sector from its SIC code, with a few hand corrections, so sector pages match the names investors expect. Guide
In plain English: 14 of the investors we track own this stock. In the latest quarter, 5 of them bought more of it and 8 sold some or all of theirs (1 bought it for the first time). That tells you what they did last quarter — not what the stock will do next.
Educational and informational only, not personalized investment advice. Based on public filings that may be delayed or contain errors; verify with the original filings. Disclaimer
Managers holding
14
+1 vs last quarter (like-for-like)
Total value held
$2.45B
Across tracked managers
Average weight ⓘOn average, how big this stock is in the portfolios that own it (its share of each manager's reported portfolio value).
0.2%
Of each manager's book
QoQ value ⓘLike-for-like: only managers that filed both quarters are compared, so a manager filing late (or confidentially) does not look like buying or selling. Includes price changes.
+$202.61M
+26.2% vs last quarter
Net shares bought
+233.2K
Est. net flow +$115.85M
Quarter activity
5 bought · 8 sold
1 new · 0 sold out
Tracked capital in this stock
Total value held (area) and number of managers (line). Dips can mean a large holder filed that quarter confidentially (e.g. Norges Bank in Q1/Q3).
Aggregate buying and selling
Net share change reported each quarter
Who owns VRTX?
🔒 The 'who added and who trimmed' chart is a Plus feature
You're viewing the Free plan. Upgrade to unlock The 'who added and who trimmed' chart — every paid plan starts with a 7-day free trial, and you can cancel in two clicks.
Who owns VRTX? — Q2 2026
Holders ranked by position size, with each one's quarter-over-quarter change.
Column filters
| # | Manager | Fund | Shares | Value ↓ | % of their portfolio | QoQ | Δ shares | Δ shares % | Est. Δ value ⓘChange in shares × this quarter's price |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank | Norges Bank Investment Management | 2.97M | $1.48B | 0.1% | — | — | — | — |
| 2 | Ken Griffin | Citadel Advisors | 510.43K | $253.55M | 0.1% | Added | +171.1K | +50.4% | +$85.01M |
| 3 | Israel Englander | Millennium Management | 468.41K | $232.67M | 0.2% | Added | +437.6K | +1419.7% | +$217.36M |
| 4 | Jim Simons | Renaissance Technologies | 320.01K | $158.96M | 0.2% | Reduced | -101.7K | -24.1% | -$50.51M |
| 5 | Two Sigma | Two Sigma Investments | 285.00K | $141.57M | 0.1% | Reduced | -93.1K | -24.6% | -$46.27M |
| 6 | Baillie Gifford | Baillie Gifford & Co | 272.56K | $135.39M | 0.1% | Added | +73.1K | +36.7% | +$36.33M |
| 7 | Tweedy, Browne & Co | Tweedy, Browne Company LLC | 40.12K | $19.93M | 1.5% | Reduced | -266 | -0.7% | -$132.13K |
| 8 | Ken Fisher | Fisher Asset Management | 24.48K | $12.16M | 0.0% | Reduced | -6.7K | -21.4% | -$3.32M |
| 9 | Torray | Torray Investment Partners | 15.21K | $7.56M | 1.0% | Reduced | -171 | -1.1% | -$84.94K |
| 10 | Ray Dalio | Bridgewater Associates | 10.87K | $5.40M | 0.0% | Reduced | -2.5K | -18.7% | -$1.24M |
| 11 | Ron Baron | Baron Capital (BAMCO) | 6.00K | $2.98M | 0.0% | Reduced | -1.5K | -20.0% | -$745.10K |
| 12 | David Shaw | D.E. Shaw & Co. | 3.10K | $1.54M | 0.0% | Reduced | -245.9K | -98.8% | -$122.12M |
| 13 | Fred Alger | Fred Alger Management | 2.97K | $1.48M | 0.0% | Added | +539 | +22.2% | +$267.74K |
| 14 | Steve Cohen | Point72 Asset Management | 2.62K | $1.30M | 0.0% | New | +2.6K | — | +$1.30M |
Column filters
No tracked manager sold out of this stock this quarter.
Politician trades
Column filters
| Politician | Date | Ticker | Asset | Type | Reported range ⓘThe dollar range the politician reported. Exact amounts are not disclosed. | Est. size ⓘOur estimate only: the midpoint of the reported range. | Owner | Account ⓘSubholding Of: the account the trade was in, as named on the report (e.g. an IRA or a brokerage account). The same stock bought on the same day in different accounts is a separate trade in each account. | Filed ↓ | Filing delay ⓘDays between the trade and the report. Over 45 days is late under the STOCK Act. | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| David J. Taylor Politician | Aug 26, 2026 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | David Taylor Trust > Schwab Joint Brokerage #1 (Home Grown) | Sep 5, 2026 | 10 days | PTR ↗ |
| David J. Taylor Politician | Jan 29, 2026 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | David Taylor Trust > Sardinia Ready Mix 401(k) - Dave | Feb 2, 2026 | 4 days | PTR ↗ |
| Julia Letlow Politician | Oct 23, 2024 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | Merrill Lynch Investment Account #025 | Jan 13, 2026 | 447 days Late | PTR ↗ |
| David J. Taylor Politician | Aug 7, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | David Taylor Trust > Schwab Joint Brokerage #1 (Home Grown) | Sep 2, 2025 | 26 days | PTR ↗ |
| Lisa McClain Politician | Dec 11, 2024 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Spouse | Charles Schwab Brokerage Account 548 | Aug 13, 2025 | 245 days Late | PTR ↗ |
| Lisa McClain Politician | Jun 11, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Spouse | Charles Schwab Brokerage Account 924 | Aug 13, 2025 | 63 days Late | PTR ↗ |
| Lisa McClain Politician | Jun 10, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale (partial) | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Spouse | Charles Schwab Brokerage Account 924 | Aug 13, 2025 | 64 days Late | PTR ↗ |
| Jefferson Shreve Politician | May 12, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale | $15,001 - $50,000 | Est. $32,500 (midpoint of reported range $15,001–$50,000) | Self | CRT - Standard Unit Trust | Jun 22, 2025 | 41 days | PTR ↗ |
| Byron Donalds Politician | Mar 20, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Self | Moran Wealth IRA | Apr 14, 2025 | 25 days | PTR ↗ |
| Byron Donalds Politician | Mar 20, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Sale | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Spouse | Moran Wealth IRA | Apr 14, 2025 | 25 days | PTR ↗ |
| Jefferson Shreve Politician | Mar 13, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Purchase | $15,001 - $50,000 | Est. $32,500 (midpoint of reported range $15,001–$50,000) | Self | CRT - Standard Unit Trust | Apr 11, 2025 | 29 days | PTR ↗ |
| Jefferson Shreve Politician | Feb 24, 2025 | VRTX | Vertex Pharmaceuticals Incorporated - Common Stock (VRTX) [ST] | Purchase | $15,001 - $50,000 | Est. $32,500 (midpoint of reported range $15,001–$50,000) | Self | CRT - Standard Unit Trust | Mar 9, 2025 | 13 days | PTR ↗ |
| Byron Donalds Politician | Dec 7, 2022 | VRTX | Vertex Pharmaceuticals (VRTX) scanned | Purchase | $1,001 - $15,000 | Est. $8,000 (midpoint of reported range $1,001–$15,000) | Spouse | — | Nov 8, 2024 | 702 days Late | PTR ↗ |